Anupam Rasayan Q3FY26 Revenue Jumps 33% YoY to ₹514.5 Crore; Acquires US Firm
Anupam Rasayan reported Q3FY26 revenue of ₹514.5 crore, a 33% YoY increase. EBITDA was ₹129.6 crore (up 7% YoY) and PAT was ₹60.6 crore (up 12% YoY). The company also announced the acquisition of US-based Jayhawk Fine Chemicals Corporation, strengthening its global presence and custom synthesis capabilities.
The significant YoY revenue growth and the strategic acquisition of a US-based company are material events that are likely to have a substantial impact on the company's future performance and market position.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT for Q3FY26. The announcement of a strategic acquisition in the US further adds to the positive sentiment.
Anupam Rasayan India Limited (ARIL) announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The company reported a consolidated total revenue of ₹5,145 million (₹514.5 crore) for Q3FY26, marking a significant year-on-year growth of 33% compared to ₹3,866 million (₹386.6 crore) in Q3FY25. The Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) stood at ₹1,296 million (₹129.6 crore) in Q3FY26, an increase of 7% YoY from ₹1,208 million (₹120.8 crore) in Q3FY25, resulting in an EBITDA margin of 25.20%. Profit After Tax (PAT) for the quarter was ₹606 million (₹60.6 crore), up 12% YoY from ₹542 million (₹54.2 crore) in the same period last year.
For the nine months of FY26, ARIL delivered consolidated revenue of ₹17,297 million (₹1,729.7 crore) with EBITDA of ₹4,024 million (₹402.4 crore), demonstrating strong year-on-year growth. A key strategic development highlighted was the signing of a definitive agreement to acquire Jayhawk Fine Chemicals Corporation in the United States. This acquisition is expected to strengthen the company's global footprint, enhance its advanced custom synthesis capabilities, and deepen its access to regulated markets and innovator customers in North America, positioning ARIL as a global specialty chemical platform.
Anupam Rasayan India Ltd. is a leading custom synthesis and specialty chemical player, with two verticals: Life science related Specialty Chemicals and Other Specialty Chemicals. The company serves over 75 domestic and international customers, including 31 multinational corporations, and operates six manufacturing facilities in Gujarat.
What to do with a filing like this
Anupam Rasayan India Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Anupam Rasayan India Limited. Read the original for the full detail.